Key result
Among patients with clinically manifest vascular disease, the median estimated 10-year risk of recurrent vascular events was 17%, which could be reduced to a median residual risk of 11% if all modifiable risk factors were at guideline-recommended targets.
Why the study?
What is the distribution of estimated 10-year risk of recurrent vascular events and residual risk at guideline-recommended targets in a secondary prevention population?
Population
6,904 patients with vascular disease, externally validated in 18,436 patients with various manifestations of…
Design
Cohort
Authors
Loading...
Substantial residual risk persists at guideline targets; leaves open whether novel therapies beyond modifiable factors are needed in secondary prevention.
Cohort (n=6,904)
No
What is the distribution of estimated 10-year risk of recurrent vascular events and residual risk at guideline-recommended targets in a secondary prevention population?
Absolute Event Rate: 11% vs 17%
Even with optimal treatment reaching guideline-recommended targets, many patients with vascular disease remain at high (>20%) 10-year risk of recurrent events, highlighting a substantial unmet medical need.
Kaasenbrood et al. (2016) conducted a cohort in Clinically manifest vascular disease (n=6,904). Guideline-recommended risk factor targets vs. Current risk factor levels was evaluated on Estimated 10-year risk of recurrent major vascular event (myocardial infarction, stroke, or vascular death). Among patients with clinically manifest vascular disease, the median estimated 10-year risk of recurrent vascular events was 17%, which could be reduced to a median residual risk of 11% if all modifiable risk factors were at guideline-recommended targets.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: